Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

Researchers assessed the prognostic significance of older age and comorbidity burden on overall survival in patients with hepatocellular carcinoma.

Despite promising Phase 3 results, safety concerns, namely liver injury, have impacted Agios stock and could affect Pyrukund's approval and market adoption. Read the full report here.

Amezalpat received fast track designation from the FDA for the treatment of patients with hepatocellular carcinoma.

On , Lion TCR announced that its mRNA-encoded T-cell receptor (TCR)-T cell therapy product Liocyx-M004 has received clearance from the U.S. Food and Drug Administration (FDA) to initiate an ...

U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for ...

Elevated fat levels in your liver can raise your chances of developing serious health issues, including diabetes, ...

Dr. Waqqas Tai is a cancer doctor who often shares health advice online. He recently revealed what the five most "lethal" ...

Amezalpat has been granted FDA fast track designation as treatment for patients with hepatocellular carcinoma.

A cancer expert has shared the five types of cancer which are considered the most "lethal", and claimed people diagnosed with ...